Search

Your search keyword '"Stéphane, Giraudier"' showing total 10 results
Start Over Author "Stéphane, Giraudier" Journal haematologica
10 results on '"Stéphane, Giraudier"'

4. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)

Author

Ronan Le Calloch, Karine Lacut, Christelle Le Gall-Ianotto, Emmanuel Nowak, Morgane Abiven, Adrian Tempescul, Florence Dalbies, Jean-Richard Eveillard, Valérie Ugo, Stéphane Giraudier, Gaëlle Guillerm, Eric Lippert, Christian Berthou, and Jean-Christophe Ianotto

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive drugs for polycythemia vera or essential thrombocythemia were recruited at our institution (Observatoire Brestois des Néoplasies Myéloprolifératives registry). They completed a one-shot questionnaire designed by investigators (Etude de l’Observance Thérapeutique et des Effets Secondaires des Traitements study). Data about complications (thrombosis, transformation and death) at any time in the patient’s life (before diagnosis, up until consultation and after the completion of the questionnaire) were collected. Sixty-five (22.7%) of 286 patients reported poor adherence (

Published
2018
Full Text
View/download PDF

5. Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients

Author

Gaëlle Fossard, Emilie Blond, Marie Balsat, Stéphane Morisset, Stéphane Giraudier, Martine Escoffre-Barbe, Hélène Labussière-Wallet, Maël Heiblig, Arthur Bert, Madeleine Etienne, Jocelyne Drai, Mohamad Sobh, Isabelle Redonnet-Vernhet, Jean-Christophe Lega, François-Xavier Mahon, Gabriel Etienne, and Franck Emmanuel Nicolini

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2016
Full Text
View/download PDF

6. Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia

Author

Jacqueline Lehmann-Che, Louis Drevon, Philippe Aubin, Elsa Miekoutima, Marie-Hélène Schlageter, Nicolas Partouche, Cecile Bally, Pierre Fenaux, Nabih Maslah, Lionel Adès, Nadia Naoui, Stéphane Giraudier, Ramy Rahmé, Norman Salomao, Bruno Cassinat, Pierre Ly, and Emmanuelle Verger

Subjects
Chemotherapy, animal structures, Myeloid, business.industry, Myelodysplastic syndromes, medicine.medical_treatment, Azacitidine, Myeloid leukemia, Hematology, medicine.disease, Leukemia, medicine.anatomical_structure, Downregulation and upregulation, Apoptosis, hemic and lymphatic diseases, medicine, Cancer research, business, neoplasms, medicine.drug
Abstract

Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1Met(APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of the transcriptional transactivation function of mutant p53. Here we show that low doses of APR on its own or in combination with AZA reactivate the p53 pathway and induce an apoptosis program. Functionally, we demonstrate that APR exerts these activities on its own and that it synergizes with AZA in TP53-mutated myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) cell lines and in TP53-mutated primary cells from MDS/AML patients. Low doses of APR on its own or in combination with AZA also show significant efficacy in vivo Lastly, using transcriptomic analysis, we found that the APR + AZA synergy was mediated by downregulation of the FLT3 pathway in drug-treated cells. Activation of the FLT3 pathway by FLT3 ligand reversed the inhibition of cell proliferation by APR + AZA. These data suggest that TP53-mutated MDS/AML may be better targeted by the addition of APR-246 to conventional treatments.

Published
2019
Full Text
View/download PDF

7. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Author

Maria Domenica Cappellini, John Porter, Amal El-Beshlawy, Chi-Kong Li, John F. Seymour, Mohsen Elalfy, Norbert Gattermann, Stéphane Giraudier, Jong-Wook Lee, Lee Lee Chan, Kai-Hsin Lin, Christian Rose, Ali Taher, Swee Lay Thein, Vip Viprakasit, Dany Habr, Gabor Domokos, Bernard Roubert, and Antonis Kattamis

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Background Following a clinical evaluation of deferasirox (Exjade®) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator, is the first to evaluate whether fixed starting doses of deferasirox, based on transfusional iron intake, with dose titration guided by serum ferritin trends and safety markers, provides clinically acceptable chelation in patients (aged ≥2 years) with transfusional hemosiderosis from various types of anemia.Design and Methods The recommended initial dose was 20 mg/kg/day for patients receiving 2–4 packed red blood cell units/month and 10 or 30 mg/kg/day was recommended for patients receiving less or more frequent transfusions, respectively. Dose adjustments were based on 3-month serum ferritin trends and continuous assessment of safety markers. The primary efficacy end-point was change in serum ferritin after 52 weeks compared with baseline.Results The 1744 patients enrolled had the following conditions; thalassemia (n=1115), myelodysplastic syndromes (n=341), aplastic anemia (n=116), sickle cell disease (n=80), rare anemias (n=43) and other transfused anemias (n=49). Overall, there was a significant reduction in serum ferritin from baseline (−264 ng/mL; P5%) adverse events were gastrointestinal disturbances (28%) and skin rash (10%).Conclusions Analysis of this large, prospectively collected data set confirms the response to chelation therapy across various anemias, supporting initial deferasirox doses based on transfusional iron intake, with subsequent dose titration guided by trends in serum ferritin and safety markers (clinicaltrials.gov identifier: NCT00171821).

Published
2010
Full Text
View/download PDF

8. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)

Author

Stéphane Giraudier, Jean-Richard Eveillard, Christelle Le Gall-Ianotto, Ronan Le Calloch, Eric Lippert, Jean-Christophe Ianotto, Valérie Ugo, Karine Lacut, Morgane Abiven, Emmanuel Nowak, Gaelle Guillerm, Florence Dalbies, Adrian Tempescul, Christian Berthou, Université de Brest (UBO), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de Médecine Interne et Maladies Infectieuses Quimper, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Laboratoire de Neurosciences de Brest (LNB), CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), Institut de cancérologie et d'hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université d'Angers (UA), Hôpital Saint-Louis, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'hématologie (Labo Hémato - BREST), Laboratoire d'hématologie, CHU Bordeaux [Bordeaux], Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Laboratoires de Intéractions Epithéliums-Neurones, Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO)

Subjects
Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Antineoplastic Agents, Article, Medication Adherence, 03 medical and health sciences, 0302 clinical medicine, Polycythemia vera, Fibrinolytic Agents, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Risk Factors, Surveys and Questionnaires, hemic and lymphatic diseases, Internal medicine, [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], Antithrombotic, Humans, Medicine, Polycythemia Vera, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, Myeloproliferative Disorders, business.industry, Essential thrombocythemia, Incidence (epidemiology), Age Factors, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, medicine.disease, Thrombosis, 3. Good health, Clinical trial, 030220 oncology & carcinogenesis, Pill, Concomitant, Female, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Thrombocythemia, Essential, 030215 immunology
Abstract

The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive drugs for polycythemia vera or essential thrombocythemia were recruited at our institution (Observatoire Brestois des Néoplasies Myéloprolifératives registry). They completed a one-shot questionnaire designed by investigators (Etude de l’Observance Thérapeutique et des Effets Secondaires des Traitements study). Data about complications (thrombosis, transformation and death) at any time in the patient’s life (before diagnosis, up until consultation and after the completion of the questionnaire) were collected. Sixty-five (22.7%) of 286 patients reported poor adherence (

Published
2017
Full Text
View/download PDF

9. CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Author

Emmanuelle Verger, Nabih Maslah, Nicolas Gauthier, William Vainchenker, Stéphane Giraudier, Bruno Cassinat, and Jean-Jacques Kiladjian

Subjects
Oncology, medicine.medical_specialty, Myeloproliferative Disorders, business.industry, Fusion Proteins, bcr-abl, Hematology, medicine.disease, BCR/ABL1 Negative, Text mining, Drug Resistance, Neoplasm, Internal medicine, Mutation, medicine, Cyclin D2, Humans, Bone Marrow Neoplasms, Letters to the Editor, business, Myeloproliferative neoplasm
Published
2020
Full Text
View/download PDF

10. Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients

Author

Franck E. Nicolini, Mohamad Sobh, Arthur Bert, Hélène Labussière-Wallet, Emilie Blond, Jocelyne Drai, Marie Balsat, Isabelle Redonnet-vernhet, Maël Heiblig, Madeleine Etienne, Gaelle Fossard, Stephane Morisset, Francois-Xavier Mahon, Gabriel Etienne, Stéphane Giraudier, Jean-Christophe Lega, Martine Escoffre-Barbe, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Départment de Biochimie, Hospices Civils de Lyon (HCL), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)

Subjects
Male, Myeloid, Homocysteine, [SDV]Life Sciences [q-bio], Coronary Artery Disease, Pharmacology, Gastroenterology, Tyrosine-kinase inhibitor, chemistry.chemical_compound, 0302 clinical medicine, infection chronique, hemic and lymphatic diseases, Prospective Studies, BCR-ABL, ComputingMilieux_MISCELLANEOUS, Age Factors, Hematology, Middle Aged, erythroleucémie, chronic phase CML, nilotinib, homocysteine, cardiovascular events, 3. Good health, Leukemia, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, patient, medicine.drug, Adult, Hyperhomocysteinemia, medicine.medical_specialty, Adolescent, medicine.drug_class, Antineoplastic Agents, Chronic phase chronic myelogenous leukemia, Drug Administration Schedule, 03 medical and health sciences, Internal medicine, medicine, Humans, Online Only Articles, Triglycerides, Aged, Retrospective Studies, business.industry, Cholesterol, HDL, medicine.disease, Imatinib mesylate, Pyrimidines, chemistry, Nilotinib, cardiovasculaire, business, Hématologie, thérapie, 030215 immunology
Abstract

Fossard, Gaelle Blond, Emilie Balsat, Marie Morisset, Stephane Giraudier, Stephane Escoffre-Barbe, Martine Labussiere-Wallet, Helene Heiblig, Mael Bert, Arthur Etienne, Madeleine Drai, Jocelyne Sobh, Mohamad Redonnet-Vernhet, Isabelle Lega, Jean-Christophe Mahon, Francois-Xavier Etienne, Gabriel Nicolini, Franck Emmanuel; International audience

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results